A Muticenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

Project Details

StatusActive
Effective start/end date1/10/23 → 30/10/26

Funding

  • Bristol-Myers Squibb Australia: A$235,200.00